Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

367 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group.
Subramanian KN, Weisman LE, Rhodes T, Ariagno R, Sánchez PJ, Steichen J, Givner LB, Jennings TL, Top FH Jr, Carlin D, Connor E. Subramanian KN, et al. Among authors: connor e. Pediatr Infect Dis J. 1998 Feb;17(2):110-5. doi: 10.1097/00006454-199802000-00006. Pediatr Infect Dis J. 1998. PMID: 9493805 Clinical Trial.
Safety and immunogenicity of palivizumab (Synagis) administered for two seasons.
Null D Jr, Pollara B, Dennehy PH, Steichen J, Sánchez PJ, Givner LB, Carlin D, Landry B, Top FH Jr, Connor E. Null D Jr, et al. Among authors: connor e. Pediatr Infect Dis J. 2005 Nov;24(11):1021-3. doi: 10.1097/01.inf.0000183938.33484.bd. Pediatr Infect Dis J. 2005. PMID: 16282947 Clinical Trial.
Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. The MEDI-493 Study Group.
Sáez-Llorens X, Castaño E, Null D, Steichen J, Sánchez PJ, Ramilo O, Top FH Jr, Connor E. Sáez-Llorens X, et al. Among authors: connor e. Pediatr Infect Dis J. 1998 Sep;17(9):787-91. doi: 10.1097/00006454-199809000-00007. Pediatr Infect Dis J. 1998. PMID: 9779762 Clinical Trial.
Safety, tolerability, pharmacokinetics, and immunogenicity of motavizumab, a humanized, enhanced-potency monoclonal antibody for the prevention of respiratory syncytial virus infection in at-risk children.
Abarca K, Jung E, Fernández P, Zhao L, Harris B, Connor EM, Losonsky GA; Motavizumab Study Group. Abarca K, et al. Among authors: connor em. Pediatr Infect Dis J. 2009 Apr;28(4):267-72. doi: 10.1097/INF.0b013e31818ffd03. Pediatr Infect Dis J. 2009. PMID: 19258920 Clinical Trial.
367 results